How should our selection for neoadjuvant chemotherapy for breast cancer change in light of COVID-19?

Topics: Breast Cancer • Radiation Oncology • Medical Oncology • NCI-CCC Tumor Board Question • University of Wisconsin • COVID-19 • NCI-CCC Breast Tumor Board Question

Answer from: Medical Oncologist at Academic Institution

I believe that some patients with low risk hormone receptor positive, HER2 negative (patients with clinical stage T1a-b N0) and those with DCIS could be safely put on endocrine therapy in order to delay surgery to minimize the risk of contracting and spreading COVID-19. It is truly much more difficu...

Comments

Medical Oncologist at Michigan State University
Is there any role for genomic profiling for ER/PR ...

Medical Oncologist at Karmanos Cancer Institute, Wayne State University
I believe that genomic profiling should be used to...

Answer from: Medical Oncologist at Academic Institution

To date, the largest analysis of outcomes in cancer patients (Liang et al Lancet Oncology Feb 2020) only include 18 patients (of 1590) with a history of cancer. Of those, only 3 had breast cancer and 2 of these 3 had a distant history of 4 years or more. The cancer cohort in this analysis were noted...

Related Questions